• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma

    2020-08-18 10:02:14DanieleDondossolaMicheleGhidiniFrancescoGrossiGiorgioRossiDiegoFoschi
    World Journal of Gastroenterology 2020年25期

    Daniele Dondossola, Michele Ghidini, Francesco Grossi, Giorgio Rossi, Diego Foschi

    Abstract Cholangiocarcinoma (CCC) is the most aggressive malignant tumor of the biliary tract. Perihilar CCC (pCCC) is the most common CCC and is burdened by a complicated diagnostic iter and its anatomical location makes surgical approach burden by poor results. Besides its clinical presentation, a multimodal diagnostic approach should be carried on by a tertiary specialized center to avoid missdiagnosis. Preoperative staging must consider the extent of liver resection to avoid post-surgical hepatic failure. During staging iter, magnetic resonance can obtain satisfactory cholangiographic images, while invasive techniques should be used if bile duct samples are needed. Consistently, to improve diagnostic potential, bile duct drainage is not necessary in jaundice, while it is indicated in refractory cholangitis or when liver hypertrophy is needed. Once resecability criteria are identified, the extent of liver resection is secondary to the longitudinal spread of CCC. While in the past type IV pCCC was not considered resectable, some authors reported good results after their treatment. Conversely, in selected unresectable cases, liver transplantation could be a valuable option. Adjuvant chemotherapy is the standard of care for resected patients, while neoadjuvant approach has growing evidences. If curative resection is not achieved, radiotherapy can be added to chemotherapy. This multistep curative iter must be carried on in specialized centers. Hence, the aim of this review is to highlight the main steps and pitfalls of the diagnostic and therapeutic approach to pCCC with a peculiar attention to type IV pCCC.

    Key words: Perihilar cholangiocarncioma; Liver resection; Biliary drainage; Neo-adjuvant therapy; Type IV cholangiocarcinoma; Klatskin tumor

    INTRODUCTION

    Cholangiocarcinoma (CCC) is the most frequent and aggressive malignant tumor of the biliary tract. It arises from the epithelial cells of a bile duct and from their progenitor cells (a group of heterogeneous dynamic cells lining the biliary tree). CCC develops either within the duct or shaping a mass infiltrating the adjacent tissue (mass forming cholangiocarcinoma)[1].

    CCC is commonly classified according to the site of invasion into intrahepatic and extrahepatic, itself divided into hilar/perihilar [or Klatskin tumor, perihilar CCC (pCCC)] and distal. Extrahepatic CCC are the most common among CCC[2]. pCCC is defined as CCC located in the extrahepatic biliary tree proximal to the origin of the cystic duct[3,4]. It is burdened by a complicated diagnostic iter and its anatomical location makes the surgical site less accessible, causing higher unresectable rates[5].

    In this review, we will focus our attention on diagnostic and surgical approach to pCCC in order to underline the key points in its management.

    EPIDEMIOLOGY AND ETIOPATHOGENESIS

    CCC is a heterogeneous group of malignancies that represent the 3% of all gastrointestinal tumors[6]. Among CCC, 75% are extrahepatic CCC and half of them pCCC. The incidence of extrahepatic CCC varies worldwide from 0.3-3.5 per 100000 inhabitants/year in North America to 90/100000 inhabitants/year in Thailand. Among Mediterranean region, the incidence is fixed around 7.5/10000 inhabitants/year[7,8]. In Italy 5400 new cases/year are expected[9]. Extrahepatic CCC represent 1% of new neoplastic diagnosis in male and 1.4% in female, with a reduction in the female sex during the last few years[10]. The median age at diagnosis is 50 years; almost null risk is reported before 40 years, while a peak is registered around 70 years[9].

    The identification of risk factors for pCCC is some-like difficult due to many reasons; first of all, papers do not often distinguish CCC into intrahepatic or extrahepatic and merge CCC with gallbladder carcinomas. Furthermore, cases are frequently isolated with no identifiable risk factors. The published risk factors can be divided in[11,12]: Known: Hepato/choledocholithiasis, hepatitis B and C infection, obesity, diabetes mellitus, congenital hepatic fibrosis, Caroli’s disease or choledocal cyst, primary sclerosing cholangitis (PSC), liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), intrahepatic litiasis and recurrent pyogenic cholangitis; suspect: Inflammatory bowel disease, smoke, asbestos, genetic polymorphisms, diabetes.

    According to these data, a surveillance program can be settled in selected patients using magnetic resonance or endoscopic-retrograde-pancreatoduodenoscopy (ERCP) (Table 1)[13-16].

    The highest relative risk is identified in liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), endemic in South-East Asia[17]. Infection spreads after the ingestion of contaminated fish; and then the flukes colonize biliary tree causing chronic infection and inflammation.

    Even if the mechanisms causing the transformation of cholangiocyte into neoplastic cells are nowadays unknown, CCC development in PSC is widely investigated. The risk for patients affected by PSC (as well as other diseases of biliary plate,e.g.Caroli’s disease) to develop CCC in their lifetime is around 3%-30%[15]. Pancreatic enzymes reflux, cholestasis and chronic inflammation leads to cholangiocyte activation, apoptosis, progression of senescence pathways and increased cellular turnover. All these mechanisms are involved in carcinogenesis: Some studies underline a common pathway (interleukin 6, cyclooxygenase-2, nitric oxide,etc.) between inflammation and malignant cellular proliferation acting on hepatic progenitor cells[18-20]. Together with this pathogenetic theory, an alternative carcinogenetic mechanism has been introduced: It is based on mitogenic pathway activation with a consequent multistep tumoral development[21]. These two mechanisms cannot be considered mutually exclusive. Indeed, in PSC patients the presence of cholangiocyte dysplasia was demonstrated together with CCC. The analyses of CCC specimens underlined a wide heterogeneity of gene mutations, however they seem to be polled according to a geographical distribution[22].

    CLASSIFICATION AND STAGING

    Macrosopic classification

    The Bismuth classification, after modified by Corlette, is well known between general surgeons (Figure 1)[23]. It is used to try to define the correct surgical approach and it is based on macroscopic tumor appearance at the pre-surgical imaging. Although this classification is largely used in literature, it has different limits: The absence of longitudinal description of the cancer extension, no relation with prognostic data, and no clearly defined resectability criteria[24,25]. Other classifications have been proposed (e.g., Memorial Sloan-kattering Cancer Centre) but none of them supplanted the use of the Bismuth-Corlette one.

    On the other hand, tumor-node-metastasis (TNM) classification is worldwide accepted to define the prognosis[4]. Since the 7thedition of America Joint Commission on Cancer (AJCC) classification, pCCC has been recognized as a separate disease from the distal CCC. Unfortunately, hystopathological evaluation of surgical specimen, together with pre-operative imaging data is needed to define the correct TMN classification. For these reasons, it cannot be used to define resectability during diagnostic iter.

    At the end of 2016, AJCC was revised and the 8thedition of TNM classification was published. Some main changes were introduced in the 8thedition to better depict pCCC prognosis[3,26,27]. T4 stage is no longer linked to Bismuth-Corlette type IV pCCC, as underlined by Ebataet al. T4 pCCC is now defined as a tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery, or unilateral second order biliary radicals with contralateral portal or hepatic artery involvement. According to the current TNM classification, N stage depends on the number of locoregional lymph nodes involved. Furthermore, stage IIIC category was introduced in TNM staging.

    Beside these changings, some comments can be pointed out: Liver parenchymal invasion does not define a metastatic disease (T2b) and represent a more favorable prognostic factor than omolateral vascular invasion (T3); the main portal vein invasion (T4) is not a surgical contraindication, but requires vascular reconstruction. A proper N stage can be achieved, according to the 8thedition, only if at least 15 lymph nodes are detected on surgical specimen. A recent paper by Ruzzenteet al[26], tried to evaluate the performance of the new TNM classification in a Western setting. Surprisingly, in this publication, the T4-staged patients had no increased risk of death compared to T1. Furthermore, the ability to predict prognosis of 8thedition N stage was not improved compared to the previous edition. These differences are probably explained by the biological behavior and surgical approach to pCCC in Western and Eastern countries[28,29].

    Microsopic morphology

    Along with the macroscopic and staging classification, pCCC can be grouped in fourpatterns according to its microscopic morphology[5,20]: (1) Periductal infiltrating: The most common pattern, characterized by an undefined annular thickening of the duct, is frequently associated to perineural and lymphatic invasion; (2) Mixed: Periductal infiltrating associated with a mass forming tumor involving biliary ducts; (3) Intraductal: Mucosal growth associated to segmental bile duct dilatation. biliaryintrapapillary mucinosus neoplasm are included in this pattern; and (4) Papillarymucinosus: This class is characterized by rich mucina secretion that clutter bile ducts. Their diagnosis is frequently associated to liver abscess.

    Table 1 Patients that should undergo to screening programs and the techniques that should be applied

    Figure 1 Schematic representation of extrahepatic and intrahepatic bile ducts (until second order) showing Bismuth-Corlette classification. CCC: Cholangiocarncioma.

    DIAGNOSIS

    Literature identifies the characteristics of an ideal diagnostic iter for pCCC: Noninvasive imaging and characterization of pCCC, correct localization of the tumor, presurgical stadiation and resectability evaluation (vascular invasion and biliary spread)[30]. Once CCC is suspected, patients must be referred to specialized surgical centers to complete diagnosis and settle a correct treatment. An incorrect diagnostic pathway exposes patients to delayed diagnosis or repetition of invasive and useless examinations[31].

    The onset of symptoms is not specific and most of the patients (> 65%-80%) are not resectable at the time of diagnosis[32-34]. pCCC identification can be anticipated by jaundice (90%) or cholangitis (10%). Almost patients subjected to screening are found asymptomatic[5]. A proposed diagnostic flow chart for pCCC is showed in Figure 2.

    Non-invasive diagnosis

    Ultrasound (US) is considered the first line examination. Even if it is weighted by operator-dependent sensitivity and specificity (55%-95% and 71%-96% respectively) in stenosis visualization, US offers valuable information (also using color-doppler) to establish the future diagnostic plan[35-37].

    Computer tomography (CT) and magnetic resonance cholangiographic sequences (MRCP) provide complementary information. CT allows a better definition of local tumor extension, vascular invasion and metastatic disease, but only small details about intraductal extension of pCCC (sensitivity and accuracy of 60% and 92% respectively). However, the introduction of multidetector-row CT (high-resolution) has increased the ability to predict intraductal biliary spread of pCCC[38], in particular when bile ducts are dilated[31].

    MRCP has the best sensitivity and accuracy (92% and 76% respectively) in identifying the extension of pCCC, but alone is not enough to establish a correct surgical strategy (e.g., lack in vascular invasion)[39,40]. The importance of a correct MRCP execution is highlighted in Zhanget al[41]review. Indeed, they demonstrated that inadequate MRCP image leads to the re-execution of the exam and up to 60% of MRCP were found incomplete or inadequate if performed in non-specialized centers.

    Positron-emissions-tomography has a marginal role in pCCC staging. It can be used to identify metastatic lymph nodes, distant metastases or clarify indeterminate lesions, especially in PSC patients[42,43]. Due to its low sensitivity (< 70%), it can be considered only in selected cases: In fact, distant metastasis are better identified using CT, while EUS is the gold standard in lymphnode staging[37].

    Invasive diagnosis

    In selected pCCC cases, diagnosis should rely on invasive examinations: ERCP, percutaneous transhepatic colangiography (PTC), endoscopic ultrasound (EUS). They should be addressed to clarify the nature of a stenosis (biopsy) or to drain bile ducts[5,32,44,45]. Indded, ERCP and PTC are not more relevant than MRCP images in visualizing biliary tree[46,47]. Parket al[48]showed an accuracy for predicting biliary confluence and intrahepatic bile duct involvement of 91%-87% for MRCP and 85%-87% for CT combined with invasive cholangiography.

    Nowadays, PTC is considered a second choice compared to ERCP due to its increased number of complications. However, Zhiminet al[49]described an increased accuracy of PTC (> 90%) in identifying the cranial border of pCCC (especially in pCCC with a proximal localization) compared to ERCP and MRCP.

    Endoscopic ultrasound has a controversial role in pCCC diagnosis and management. It provides accurate information about localization of biliary lesions, peribilary tissue involvement, visualization of lymph nodes, hepatic vessels involvement, and it ultimately allows a proper preoperative staging[5,16,32,44,45,50]. However, EUS and EUS fine-needle-aspiration (FNA) sensitivity is reduced from distal to proximal lesions (100% and 83% respectively)[51]. Definition of N staging using EUS needs further studies: Clinical trials are ongoing to identify the role of lymph nodes FNA in predicting pre-operative N stage[52].

    Cytological sampling can be obtained through brushing or FNA. It is usefull in nonresectable pCCC or before surgery when diagnosis is not confirmed by non-invaisve techiniques[5,44]. EUS-FNA could also be usefull for cases with negative ERCP-examination[53]. The brushing sensitivity ranges from 20%-40%[54,55]while 79%-83% for FNA[51]. Overall specificity is 92%-100% (the number of cases performed in a hospital highly increase specificity and sensitivity)[16,56]. The low global negative predictive value of cytological sampling using ERCP, PTC and EUS does not exclude the presence of pCCC when a non-neoplastic report is given. It is worth highlighting that, although FNA or brushing allows a proper diagnosis, they are charged by an increased risk of seeding. Only small data are reported on this topic[7,52]. Seeding is a major concern especially during EUS FNA: Indeed, the fine-needle crosses duodenal bulb and peritoneal cavity to sample the pCCC. For these reasons, EUS FNA is contraindicated before liver transplantation[16,52].

    Figure 2 Diagnostic and therapeutic work-flow for perihilar cholangiocarncioma.1If cytological confirmation is needed (negative carbohydrate antigen 19-9, positive immunoglobulin G4, and confounding diagnosis at imaging); interrupted line, consider neo-adjuvant therapies. US: Ultrasound; CT: Computed tomography; MR: Magnetic resonance; CA 19-9: Carbohydrate antigen 19-9; BIL: Bilirubin; IgG4: Immunoglobulin G4; ERCP: Endoscopic-retrogradepancreatoduodenoscopy; EUS: Endoscopic ultrasound; FRL: Future remnant liver; PVE: Portal vein embolization; ALPPS: Associated liver partition to portal vein ligation for staged hepatectomy; PTC: Percutaneous transhepatic colangiography; CHT: Chemotherapy; RT: Radiotherapy.

    A further improvement in endoscopic diagnosis is intraductal-EUS. Even if it has almost 91% accuracy[57], it has a lack in tissue sampling and a reduced radial visualization (max 2 cm). Cholangioscopy allows direct visualization of bile duct epithelium and FNA execution and has a sensitivity and specificity of 90% and 96%, and 85% and 100%, respectively[58]. Confocal laser endomicroscopy has high sensitivity, specificity and accuracy (89%-71%-82%[59]). However, many concerns are reported concerning standardization and reproducibility of this diagnostic tool, for this reason it is not suggested for a routine use[16].

    Serum markers

    Carbohydrate antigen (CA) 19-9 is elevated in 85% of pCCC, but it has a variable sensitivity (33%-93%) and specificity (67%-98%) with low positive predictive value (16%-40%). A CA 19-9 cut-off of 129 ng/dL should raise specificity at 70%[2,7,56,60-62]. The main confounding factor is jaundice: A re-evaluation after biliary decompression (BD) is suggested. Another tumor marker is CA-125, but it is seldom used outside clinical trials[7]. Immunoglobulin G4 (IgG4) are specific immunoglobulines produced during IgG4 cholangiopathy, a rare autoimmune disease associated with pancreatitis. The presence of IgG4 suggests IgG4 cholangiopathy, susceptible to steroids’ treatment rather than surgery[63]. New diagnostic approaches are based on liquid biopsy: Detection of cholangiocarcinoma cell-free DNA and circulating tumor cells. Even if some authors reported a usefulness of miRNA measured in bile and blood in pCCC diagnosis, further studies are needed and it probably has a prognostic, more than a diagnostic, role[64-66].

    TO DRAIN OR NOT TO DRAIN

    BD is a key point during diagnostic and therapeutic management of the pCCC patients. A wide debate is open in literature about this topic and BD must be evaluated according to patient clinical conditions.

    Diagnosis and staging in patients with a suspected pCCC are better obtained in absence of foreign bodies in biliary tree. Incorrect indication to BD is one of the most frequent causes of delayed or miss-diagnosis, especially as regards the intraductal extension of the tumor. Hosokawa and colleagues[31]demonstrated that biliary drainage placed before proper diagnosis and staging leads to a higher rate of non-R0 resections. They hypothesized a confounding factor due to artifacts and reduction of the bile duct dilatation.

    Sepsis secondary to cholangitis non-responsive to pharmacological treatment is the only absolute indication to BD. Jaundice, itching or cholangitis are not indications to drain the biliary tree during diagnostic time if the patient is a candidate for liver resection. The use of plastic stents or naso-biliary drainages is more suitable than the use of metallic stents. Indeed the fisrt are easily removed to obtain a correct diagnosis[11,5].

    Once surgical indication is established, biliary decompression is anyway debated. Wide accordance on drainage is achieved when a two-step procedure (two-setp hepatectomy or portal vein embolization followed by hepatectomy) is needed to increase the future remnant liver (FRL) volume. Indeed, standard surgical procedure in pCCC requires the resection of a large portion of “healthy” liver parenchyma and liver hypertrophy could be needed before surgery. When a two-step procedure is programmed, whilst the risk of bacterial colonization is increased, BD can improve FRL hypertrophy[67]and could reduce morbidity and mortality[68,69]. In this setting, Eastern surgeons are more likely to use a naso-biliary drainage[31], while Western specialists prefer endoscopic stents[29].

    Once a one-step hepatectomy is programmed, BD is associated to high risk of septic shock secondary to retrograde cholangitis that could exclude resectable patient from surgery[70]. In a multicenter study, Farges and colleagues[71]reported an increased mortality after BD in patients that underwent left hepatectomy (mainly due to postoperative septic shock) (adjusted OR 4.06, 95%CI 1.01 to 16.3;P= 0.035), while a decreased mortality rate, due to reduction of post-operative liver failure, was observed after right-side hepatectomy (adjusted OR 0.29, 95%CI: 0.11-0.77;P= 0.013). According to their data, the authors suggested that when a right-side hepatectomy is planned in jaundiced patients, BD should be performed and surgery scheduled when bilirubin < 3 mg/dL. Conversely, Celottiet al[72], in their meta-analyses, underlined that patients that underwent pre-operative BD had an increased rate of morbidity and wound infections with no advantages on post-operative mortality. While only a selective use of pre-operative BD is suggested (e.g., patients affected by cholangitis) if one-step hepatectomy is planned, randomized prospective studies are needed to better depict the indications for BD.

    BD can be achieved through percutaneous [Percutaneous Transhepatic Biliary Drainage (PTBD)] or endoscopic (plastic or metallic stent or naso-gastic tube) approach according to hospital expertise. No definitive data are published on the best technique for BD[67]. Table 2 summarizes pros and cons of the two techniques. A recent paper by Higuchiet al[73]estimated a comparable patient survival and morbidity in patients undergoing PTC or ERCP. While increased post-operative tumor dissemination in PTC group is reported, an increased rate of infection is highlighted in ERCP patients[74,75]. Even if some authors reported the overall superiority of PTC on ERCP[74-76], a recent randomized control[77]trial was prematurely stopped due to the higher rate of presurgical mortality among PTC patients (PTCvsERCP: 41%vs11%). Until PTBD the superiority of a technique will be demonstrated, ERCP with endoscopic stent placement should be considered the first line technique to obtain BD[78]. When curative intent resection is not feasible, ERCP must be pursued in a patient oriented approach.

    TREATMENT

    Patient and resecability assessment

    Due to the late onset of symptoms and the aggressive nature of pCCC, less than 50% of the patients are surgically resectable at diagnosis[5]. The main criteria involved in resecability evaluation are highlighted in Table 3.

    A recent paper provides a pre-operative risk score designed to predict the risk of intraoperative metastatic disease or locally advanced pCCC (i.e. unresectable) and the post-operative mortality[79]. Through the evaluation of 566 resected pCCC, the authors identified 5 objective criteria (bilirubin > 2 mg/dL; Bismuth classification at imaging; portal vein and hepatic artery involvement at imaging; suspicious lymph node on imaging) that allow the definition of 4 risk categories. An interesting perspective can be the adoption of this score to define the need for up-front neo-adjuvant chemotherapies in high-risk patients.

    According to the complexity of surgical approach, resectability decision is strictly connected to a careful evaluation of the patient’s performance status, liver, cardiac,respiratory and kidney function[45]. Nutritional status must be evaluated before surgery and all efforts should be directed towards counterbalancing malnutrition progression. Poor nutritional condition leads to reduced survival, increased post-operative complications and prolonged hospital stay[80-82].

    Table 2 Main advantages of two the two techniques available to obtain bile duct drainage

    Table 3 Criteria that can be used to identify non-resectable patients

    Advanced age was identified as one of the main changings in the characteristics of pCCC population. Despite the advanced age, the rate of resectable patients (70%) was similar in octogenarian and non-octogenarian patients. Post-surgical overall survival was not reduced by age even if a carefully selection of patients is needed. Indeed, 30% of octogenarians (vs6% of under 60 years) were excluded to surgery for poor performance status and poor liver function[83].

    Surgical resection

    Curative approach to pCCC relies on free surgical margins. Indeed, after R0 resection, 5-year survival reaches 20%-42% in association or not with chemotherapy[8,5,45,67]. The localization of pCCC is one of the most important factors influencing surgical strategy: Isolated bile duct resection is applicable in Bismuth Corlette type I pCCC, while resection of the bile duct confluence is associated to major hepatectomies in the other types. The quantity of liver parenchyma and the number of segments resected depend on the localization of the cranial border of pCCC: Right hepatectomy + S4 in Bismuth-Corlette type IIIa and left hepatectomy in type IIIb. As surgical procedures (especially in type IIIa) require the resection of more than 50% of the liver, post-surgical hepatic failure must be avoided. FRL and liver functional reserve need to be carefully evaluated through liver functional tests (e.g., indocyanine green clearance), imaging techniques and, if possible, liver biopsy. If the predicted FRL is less than the necessary (< 40% in hepatopatic patients, < 30% in normal liver), a single step hepatectomy is related to an increased risk of liver failure and death[84,85]. A two-step procedure (associated liver partition to portal vein ligation for staged hepatectomy or simple portal vein ligation) or pre-operative portal vein embolization (PVE) must be settled. PVE is largely adopted in the Eastern Countries (55% of the cases compared to the 7% of Western Countries)[29]. A recent study by Leeet al[86]developed a score to evaluate the risk of “small for size” after resection. They included in their analyses FRL, intraoperative blood loss and prothrombine time > 1.2. Olthofet al[69], in the same year, proposed their own score based on FRL, jaundice at presentation, preoperative cholangitis and immediate post-operative bilirubin > 2.9 mg/dL. While the authors underlined that pre-operative BD increases FRL hypertrophy, post-BD cholangitis reduced the positive effect of biliary decompression on post-operative liver failure rate. Even if PVE is more frequently used in Eastern countries, the rate of post-surgical liver failure is similar to Western ones. A more aggressive approach to liver vascular pedicle, a larger lymphadenectomy and an increased rate of intraoperative transhepatic biliary drainage in the Eastern Countries can counterbalance the effect of PVE hypertrophy[87].

    Regardless of the type of hepatectomies, resection of caudate lobe is considered the gold standard. Caudate lobe’s bile ducts open out at bile duct bifurcation and are frequently infiltrated by pCCC. Its removal increases the percentage of R0 resections (59%-87%) with better results in long-term survival (5 years survival from 33% to 44%, resection S1vsnon-resection HR 3.03)[88,89].

    Curative surgical strategies cannot leave aside from a histological intraoperative evaluation of bile duct margins (cranial and caudal). Bile duct R0 resection is one of the most important factors influencing long-term follow-up. If neoplastic cells are detected at frozen section, surgical resection will be enlarged till feasible to obtain R0 (60% of the cases[90]). The growth of pCCC is intraluminal and the perineural spread is frequent. A resection of 1 cm above pCCC localization must be considered in the infiltrative type[91], as well as 2 cm in the papillary/mass-forming[92]. A debate in literature is open to understand the results of high-grade dysplasia detection on bile duct margins. While some studies reported comparable patients’- but reduced disease free – survival, other studies showed a reduced 2 and 5-year disease specific survival in N0 R1-high grade-dysplasia patients (2-year, 76.7%vs84.3%; 5-year, 37.5%vs69.3%)[73,93].

    Portal vein resection can be headed if focal portal invasion (< 2 cm) of the main trunk is demonstrated. Indeed, portal vein resection does not affect post-resection outcome[4,90,94]. Conversely, hepatic artery resection is related to an increased surgical risk, without a demonstrated positive influence on long-term results[95,96].

    In 2012 Neuhauset al[91]proposed a new approach to liver resection in type IIIa pCCC, called “en bloc resection”. In his paper, Neuhaus presented a series of 100 type IIIa pCCC patients that received two different surgical treatements according to the tumor localization: “en bloc resection” in tumors located close to hepatic hilum (n= 50) and standard resection in the others (n= 50). “En bloc resection” consisted in right enlarged hepatectomy + S1, lymphadenectomy and en bloc resection of biliary confluence, extrahepatic bile duct, portal vein bifurcation and right hepatic artery (portal vein reconstruction is needed). 3 and 5-year survival was superior in “en bloc” group (35% and 25%vs65% and 58% respectively) without an increase in surgical complications. Other authors adopted this approach with reported comparable results[97]. The “en bloc resection” is not feasible in left hepatectomy because the no touch approach on hilum is impossible, unless resection and reconstruction of the right hepatic artery are being considered.

    In 2017, Kawabataet al[98]proposed their own surgical technique based on reduced liver manipulation and tumor spread. They described an ab-initio parenchymal transection prior to liver mobilization. Two-year survival was increased in the study group (95%vs58%) with a decrease in surgical complications.

    Bismuth-Corlette Type IV pCCC deserves a peculiar consideration (Table 4). It was considered a surgical contraindication for several years due to the bilateral bile duct invasion. However, in the last few years, the surgical approach to this type of pCCC changed due to the Japanese group’s contributions. In 2018, they published[99]a series of 216 patients with Bismuth Corlette type IV pCCC that underwent surgical resection: R0 resection was achieved in 76.2% of the cases, post-surgical morbidity was 41.6% and the 5-year survival was superior in the resected patients (32.8%vs1.5%). Even if the resection of type IV pCCC is feasible and the results are promising, two main concerns are emerging: An undiagnosed vascular invasion often detected at histopathological evaluation and the high rate of N positive specimens[100,101]. The adoption of an en-bloc approach can be suggested in this type of pCCC to avoidunexpected vascular invasion diagnosis. Furthermore, neoadjuvant chemotherapy can be useful in type IV pCCC to select chemo-responsive tumors, reduce the possible futile resections and improve the extent of R0 rate.

    Table 4 Articles reporting resection of type IV perihilar cholangiocarncioma according di bismuth

    Liver transplantation

    In unresectable pCCC, liver transplantation (LT) can be considered within research protocols and with strict inclusion criteria[102]. These criteria are: Tumor smaller than 3 cm, no evidence of lymph node involvement or metastatic disease, and no prior percutaneous or endoscopic biopsy[103]. The initial results of LT for pCCC were poor. Indeed, overall survival (OS) following LT alone for incidentally diagnosed pCCC in PSC are < 40% at 3-year[104]. LT for pCCC gained new enthusiasm with the publication of Mayo Clinic results: In their studies they identified the risks for disease progression and recurrence, and a multimodal therapy (neoadjuvant chemoradiation therapy is mandatory prior to listing) was successfully applied. In the published series of LT performed at Mayo Clinic, the LT group with neoadjuvant chemoradiation (38 patients) achieved better 1 year (92%vs82%), 3 years (82%vs48%), and 5 years (82%vs21%) overall survival (OS) when compared with the resection group (26 patients). Consistently, the LT group experienced lower post-transplant recurrence (13%vs27%)[105]. Ethunet al[106]compared 191 patients that underwent curative resection with 41 patients that received LT (with Mayo Clinic Protocol) for pCCC. In LT group, 38% of the patients were excluded. Patients who underwent transplant for pCCC showed improved OS compared with resection (5-year: 64%vs18%;P< 0.001). The same results were obtained if patients with tumors < 3 cm with lymph-node negative disease and without PSC patients from resection group (5-year: 54%vs29%;P= 0.03).Resective surgery in pCCC is the standard of care for suitable patients outside the setting of PSC[107]. To date, even if there are no randomized controlled trials, LT after aggressive neoadjuvant therapy (including external beam and transluminal radiation, as well as systemic chemotherapy) seems like an adequate treatment for both unresectable pCCC, as well as pCCC arising in the setting of PSC[108].

    Laparoscopic exploration

    The role of laparoscopic exploration (LE) decreased over time together with the increase of sensibility and specificity of imaging techniques. Routine LE is not recommended, but it can be useful in T2/T3 pCCC according to AJCC classification or type III and IV according to Bismuth-Corlette[92,109]. LE is the only way to detect peritoneal metastasis prior to laparotomy, due to the low predictive value of noninvasive technique. Furthermore, routine opening of the lesser sac during LE can help in detecting metastatic lymphnode of hepatic artery (N2 stage)[110]. A recent meta-analysis[111]collected 8 studies evaluating the role of LE: 32.4% of the patients were found unresectable at exploration with a sensitivity of 56% and a specificity of 100%. In another study, sensitivity of LE increased from 24% to 41% using intraoperative ultrasound[112].

    Lymphadenectomy

    Lymphadenectomy is an essential part of the surgical intervention, as well as bile duct and liver resection. In pCCC, hilar, hepatic artery, portal vein, bile duct, celiac trunk and retroduodenal lymph nodes must be resected. The role of lymphadenectomy is to obtain an adequate post-surgical staging, even if some authors reported a survival benefit[88,113,114]. The 8thedition of TNM classification identifies 15 lymph nodes as the minimum number to obtain an adequate N staging (N1 when 1 to 3 regional lymph nodes are positive, N2 when more than 4 regional lymph nodes are positive)[4]. Regional lymph nodes are located in the hepatic hilum and in the hepatoduodenal ligament (pericholedochal nodes). The first systematic review on lymphadenectomy was published in 2015[115]. Beside AJCC classification, Kambakambaet al[115]rose criticism about the minimum number of dissected nodes. Indeed, in their review, only 9% of the series reported a number of dissected lymph nodes > 15, while N positivity ranged from 31% to 58%[116,117]. Their analyses showed that 7 is the number of lymph nodes that ensures the highest detection rate of N1 and the lowest rate of potentially understated N0 patients. The impact on survival of extended lymphadenectomy (> 15 lymph nodes) is debated, because it does not improve 5-year survival and median OS with an increased rate of surgical complications[5]. The presence of malignant cells within dissected lymph nodes (N1) has a detrimental impact on patient survival: 3-year survival 35%vs10% in N0vsN1 patients[115]. It was recently suggested that the presence of a small number of metastatic lymph nodes (lymph nodal ratio < 0.2 or number of lymph node < 4) does not exclude good long-term survival[114,118].

    Chemotherapy, radiotherapy and palliative treatments

    The role of neo-adjuvant chemotherapy in pCCC is not clearly identified and it is mostly adopted in clinical studies.

    The Mayo Clinic protocol combined neoadjuvant chemosensitization with 5-fluorouracil, external beam radiotherapy plus brachytherapy boost and orthotopic liver transplantation for patients with stage I and II pCCC. In a retrospective series, thirty-eight patients underwent liver transplantation while 54 patients were explored for resection. Patients receiving transplantation had better one-, three- and five-year survival (92%, 82% and 82%) compared to resection (82%, 48% and 21%,P= 0.022). Transplanted patients had fewer recurrences compared to resection (13%vs27%)[105]. The ongoing phase III TRANSPHIL trial is comparing resection with neoadjuvant chemoradiotherapy capecitabine-based and orthotopic liver transplantation[102].

    Resected patients, except the R0 pT1N0M0 ones, as well as non-resected patients must undertake chemotherapy with adjuvant intent. The role of adjuvant chemoradiotherapy is not well defined due to the lack of data from randomized trial[8]. On the contrary, the phase III randomized BILCAP trial, comparing adjuvant capecitabine with observation in resected biliary tract cancers, showed an increased OS for the experimental arm in the protocol-specified sensitivity analysis (adjusting for minimisation factors, nodal status, grade and gender). Specifically, median OS in the capecitabine arm was 53 movs36 mo in the observation group (P= 0.028)[119]. Diversely, the phase III Prodige 12-Accord 18 trial, comparing chemotherapy with oxaliplatin and gemcitabinevsobservation after resection, failed to show an increase in OS (P= 0.74)[120].

    A further phase III study, comparing cisplatin and gemcitabine treatmentvsobservation (ACTICCA-1) is open and recruiting patients[121].

    A meta-analysis evaluating studies of adjuvant chemotherapy, chemoradiotherapy or radiotherapy in biliary tract cancers found a nonsignificant improvement in OS compared with adjuvant treatment compared with surgery alone (P= 0.06). However, patients treated with chemoradiotherapy (OR 0.61) or chemotherapy (OR 0.39) had greater benefit with compared to radiotherapy alone (OR 0.98,P= 0.02) and, specifically, the greatest benefit was in those patients with nodes positive (OR 0.49,P= 0.004) and R1 disease (OR 0.36,P= 0.002)[122]. Another meta-analysis of randomized and non-randomized studies confirmed the improvement in OS given by adjuvant chemotherapy, with a 41% of risk of death reduction compared with observation after resection (HR 0.59,P< 0.0001)[123]. In contrast, a meta-analysis of randomized clinical trials showed no effect of adjuvant treatment on OS improvement (HR 0.91) and a mild improvement in recurrence-free survival (HR 0.83). Neither the lymph-node positive (HR 0.84) nor the surgical margin positive subgroups (HR 0.95) had an OS prolongation with adjuvant treatment[124]. Nassouret al[125]retrospectively analyzed the National Cancer Database to evaluate the role of adjuvant chemotherapy (AT) on pCCC. They found the patients that received AT were younger, with a higher pathological T and N staging, a higher rate of non-R0 resections and a longer hospital stay than patients that did not undergo AT. After a propensity match analyses, they found that AT had a beneficial role on 5-year survival in all resected patients, especially in high risk (non-R0 resection) ones. Furthermore, an advantage on 5-year survival was showed for patient that underwent chemo-radiotherapy compared to chemotherapy alone.

    In case of locally-advanced unresectable disease, the role of radiation therapy remains unclear[8]. A phase II trial compared gemcitabine plus oxaliplatinvschemoradiotherapy with 5-fluorouracil and cisplatin. The trial closed before completion due to slow recruitment, showing an increased median OS (19.9 movs13.5 mo, HR 0.69) and progression free survival (11.0 movs5.8 mo, HR 0.65) for the chemotherapy arm[126]. A small series using image-guided intensity-modulated radiation therapy both in gallbladder and extrahepatic bile ducts cancers demonstrated the feasibility of the procedure, allowing safe dose escalation[127].

    Exclusive chemotherapy remains a suitable option in case of unresectable disease. The phase III UK ABC-02 study has established the cisplatin/gemcitabine chemotherapy as the new standard of care in patients with advanced biliary tract cancer. Median survival was 11.7 for the combination therapy compared with 8.1 mo for the gemcitabine only comparator arm (P< 0.001)[128]. The benefit of the combination was present independent of age (inferiorvssuperior to 65 years), gender, primary tumour site (intravsextrahepaticvsgallbladdervsampullary), stage of disease (locally advancedvsmetastatic) and previous therapy (surgeryvsstenting)[129]. In case of altered renal function, oxaliplatin may be used instead of cisplatin, while in case of poorer clinical conditions, gemcitabine monotherapy may be a choice[8].

    Beyond failure of first line treatment, evidence is scarce. A recent systematic review of the literature gathering 25 non-randomized prospective and retrospective studies reported a median progression-free survival (mPFS) and median overall-survival (mOS) of 3.2 and 7.2 mo, respectively[130]. A large multicenter Italian survey and pooled analysis with published data found a mPFS of 3.1 and median OS of 6.3 mo[131]. Recently, the results of a phase III trial (ABC-06) comparing modified FOLFOX to best supportive care found an advantage in mOS (6.2 movs5.3 mo) with adjusted hazard ratio (HR) 0.69. Patients treated with FOLFOX had a prolongation of median radiological PFS or 4 mo. Moreover, the study showed a 1% rate of complete responses, 4% of partial responses and a 28% of cases had disease stabilization. The overall disease control rate was 33%. Due to the results of this trial, modified FOLFOX should be considered the standard of care in the second-line treatment of BTCs[132].

    Isocitrate dehydrogenase isoenzyme 1 (IDH1) mutations are present in 15% of patients with CCC. Recently, the results of treatment with ivosedinib, an oral smallmolecule inhibitor of mutant IDH1 (mIDH1), have been presented. In patients with mIDH1 progressed to first line treatment, mPFS was 2.7 mo with ivosedinibvs1.4 mo for placebo (HR 0.37,P< 0.001). MOS was 10.8 mo for ivosedinibvs9.7 mo for placebo (10.8 movs9.7 mo for placebo, HR 0.69,P= 0.06). However, mOS for placebo decreased to 6 mo after considering a 57% crossover-rate from placebo to experimental treatment and the difference in mOS between ivosedinib and placebo became statistically significant (HR 0.46,P= 0.0008)[133]. Ivosedinib is the first targeted molecular agent showing efficacy in the treatment of advanced CCC and its use will probably become a standard in the second-line treatment of mIDH1 CCC.

    In patients with an estimated survival longer than 3 mo, bile duct decompression should be reached. Percutaneous or endoscopic approaches are both possibile. ERCP has the advantage of a totally internal stent, without the discomfort of PTBD (less pain and aesthetic impact). On the other hand, endoscopic stents are not easy to arrange in type III and IV pCCC. Percutaneous transhepatic biliary stent placement is an effective alternative to endoscopic stent to relieve cholestasis77. Combined seed intracavitary irradiation with125I can be applied to obtain a better stent patency and survival[134,135].

    OUTCOME AND RESULTS

    Survival after pCCC diagnosis is poor and frequently accompanied by a prolonged hospitalization and a wide use of diagnostic and therapeutic techniques. Median survival is 12 mo in patients not susceptible to surgery and 38 (range 25-40) mo in radically resected patients. Koerkamp and colleagues in 2015[136]evaluated a population of 306 patients that underwent surgical resection for pCCC: Overall 5-year survival was 35%, while it increased to 50% in the 122 (42%) patients N0R0 resection. Excluding R2 patients and patients with intra-hospital death, the median time to recurrence was 31 mo with a 3-year survival after recurrence of 18%. Eastern postoperative survival is slightly better that Western one (median OS of 56 movs43 mo respectively,P= 0.028), depicting a possible more aggressive behavior of pCCC in Western world[29].

    In literature, many variables influence 3 and 5-year survival: Resection margins, type of resection, T stage, N stage, staging, lymphovascular invasion and caudate lobe invasion[88,137,138]. T stage and N positivity are burdened by the highest Hazard Ratios: N1 HR 2.32 (5-year survival N1vsN0 11%vs35%) and T3-4 HR 1.86 (5-year survival T1-2vsT3-4 47%vs19%)[137]. R0 resection was recently underlined as the main factor influencing the outcome, irrespective of the tumor staging[31,139]. Three and five-year recurrence-free survival was 57% and 49% in R0 resection, while 31% and 16% in R1 resection. In stage I, II and III, R0 resection was directly related to segment 1 resection and age > 56 year[31]. Lymphovascular invasion was identified as one of the detrimental prognostic factors on patient and disease free survival. Its role was investigated in lymph nodes positive and negative patients and in both was identified as a detrimental factor[138]. Furthermore, lymphovascular invasion resulted in an increased percentage of patients with lymph nodes metastasis, but not with a decrease in R0 rate, also in Bismuth-Corlette tipe IV pCCC[101,137,140].

    In 2017, van Vugtet al[95]evaluated the impact of vascular invasion on 674 patients affected by pCCC. Median OS was considered independently from curative resection. They found that any hepatic artery involvement is related to poor prognosis (median OS: 16.9 (13.2-20.5) movs10.3 (8.9-11.7) mo,P< 0.001), while unilateral or main portal vein involvement was not related to reduced median OS [14.7 (11.7-17.6) movs13.3 (11.0-15.7) mo,P= 0.116]. This paper confirmed the results provided by other authors and highlighted the necessity of a further modification of the 8thAJCC classification. Indeed, the T4 classification does not discriminate arterial or main portal vein infiltration with a reduced ability to predict patient outcome[26].

    The resection benefits have to deal with the high surgical morbidity and mortality of pCCC. In both Western and Eastern Centre, 90-d surgical mortality ranges around 10%.

    The 5-year survival rate for perihilar cholangiocarcinoma in patients receiving a liver transplant is greater than 70%[105], although these data are affected by selection bias. A number of factors were identified as predictors of outcomes in pCCC liver transplantation: Elevated CA 19-9, portal vein encasement, perineural invasion and absence of vital tumor at explant histopathological examination[140-142]. Recent evidence showed that overall survival is affected by the amount of necrotic tumor after neoadjuvant therapy (patients with minimal response were 9.0 times more likely to die than patients with a complete tumor necrosis) and by lymphovascular invasion[140].

    CONCLUSION

    In conclusion, perihilar cholangiocarcinoma is characterized by high mortality and low rate of resectable patients. The main issue for surgeons is to obtain the most rapid and accurate diagnosis. For this reason, patients must be referred to specialized centers after a suspect diagnosis. Biliary drainage is an important tool in non-resectable patients and in those that are candidate to two-stage hepatectomy. It must be obtained after a definitive diagnosis. Even if surgery represents the only curative option, it is still charged by reduced long-term survival.

    ACKNOWLEDGEMENTS

    Authors would like to thank “Associazione Italiana Copev per la prevenzione e cura dell'epatite virale Beatrice Vitiello- ONLUS” for the valuable support and Erica Bosco for langue review.

    我的老师免费观看完整版| 啦啦啦中文免费视频观看日本| 18禁裸乳无遮挡免费网站照片| 久热久热在线精品观看| 色5月婷婷丁香| 男的添女的下面高潮视频| 精品国产三级普通话版| 一夜夜www| 久久精品夜色国产| 国产午夜精品一二区理论片| 亚洲欧美精品自产自拍| 天堂√8在线中文| 最近手机中文字幕大全| 精品亚洲乱码少妇综合久久| 精品国产露脸久久av麻豆 | 两个人视频免费观看高清| 国产中年淑女户外野战色| 黄色欧美视频在线观看| 1000部很黄的大片| 成人特级av手机在线观看| 好男人在线观看高清免费视频| 99热这里只有精品一区| 在线a可以看的网站| 亚洲欧洲国产日韩| 一区二区三区免费毛片| 亚洲不卡免费看| 一个人看视频在线观看www免费| 国产黄色免费在线视频| 嫩草影院精品99| 能在线免费观看的黄片| 久久久欧美国产精品| 久久热精品热| 欧美性猛交╳xxx乱大交人| 水蜜桃什么品种好| 国产精品人妻久久久久久| 精品人妻偷拍中文字幕| 搡老乐熟女国产| 国产美女午夜福利| 久久亚洲国产成人精品v| 亚洲激情五月婷婷啪啪| 美女xxoo啪啪120秒动态图| 99热6这里只有精品| 久久久精品免费免费高清| 亚洲精品aⅴ在线观看| 爱豆传媒免费全集在线观看| 简卡轻食公司| 亚洲欧美成人精品一区二区| 国产av在哪里看| 久久久精品94久久精品| 久久精品久久久久久久性| 亚洲精品一二三| 男人舔奶头视频| 久久精品综合一区二区三区| a级毛色黄片| 91精品一卡2卡3卡4卡| 午夜日本视频在线| 视频中文字幕在线观看| 嘟嘟电影网在线观看| 久久久久久久久久成人| 免费播放大片免费观看视频在线观看| 丰满少妇做爰视频| 国产探花在线观看一区二区| 亚洲精品日韩在线中文字幕| 欧美日韩视频高清一区二区三区二| 日韩一区二区三区影片| 日日摸夜夜添夜夜添av毛片| 欧美日韩精品成人综合77777| 国产黄片视频在线免费观看| 欧美高清成人免费视频www| av网站免费在线观看视频 | 日日啪夜夜爽| 三级国产精品欧美在线观看| 欧美精品国产亚洲| a级毛色黄片| 欧美+日韩+精品| 亚洲成人精品中文字幕电影| 色播亚洲综合网| 极品教师在线视频| 亚洲av二区三区四区| 亚洲欧美成人综合另类久久久| 一个人观看的视频www高清免费观看| 狠狠精品人妻久久久久久综合| 99久久九九国产精品国产免费| 亚洲欧洲国产日韩| 日韩亚洲欧美综合| 小蜜桃在线观看免费完整版高清| 亚洲精品,欧美精品| 欧美性猛交╳xxx乱大交人| 亚洲精品456在线播放app| 久久精品国产亚洲av涩爱| 3wmmmm亚洲av在线观看| 午夜老司机福利剧场| 国产成人a区在线观看| 永久免费av网站大全| 一级a做视频免费观看| 水蜜桃什么品种好| 不卡视频在线观看欧美| 99热网站在线观看| 午夜福利视频1000在线观看| 天堂av国产一区二区熟女人妻| 久久精品人妻少妇| 搡老妇女老女人老熟妇| av黄色大香蕉| 男的添女的下面高潮视频| 综合色av麻豆| 国产一级毛片在线| 精品不卡国产一区二区三区| 精品久久久久久久久av| 青春草国产在线视频| 精品少妇黑人巨大在线播放| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 好男人在线观看高清免费视频| 秋霞伦理黄片| 精华霜和精华液先用哪个| 免费观看无遮挡的男女| 亚洲天堂国产精品一区在线| 久久久午夜欧美精品| 国产综合精华液| 九九爱精品视频在线观看| 熟女电影av网| 国产成人福利小说| 18禁动态无遮挡网站| 亚洲av二区三区四区| 免费不卡的大黄色大毛片视频在线观看 | 国产精品不卡视频一区二区| 欧美日韩在线观看h| 亚洲欧美日韩卡通动漫| 国产乱人偷精品视频| 国产熟女欧美一区二区| 少妇的逼好多水| 非洲黑人性xxxx精品又粗又长| 欧美激情国产日韩精品一区| 亚州av有码| 成人性生交大片免费视频hd| 国产精品不卡视频一区二区| 高清日韩中文字幕在线| 免费黄色在线免费观看| 国产精品一区二区在线观看99 | 狠狠精品人妻久久久久久综合| 人体艺术视频欧美日本| a级毛片免费高清观看在线播放| 成年免费大片在线观看| av天堂中文字幕网| 最近视频中文字幕2019在线8| 女的被弄到高潮叫床怎么办| 国产免费一级a男人的天堂| 色综合站精品国产| 亚洲精品乱码久久久v下载方式| 夜夜看夜夜爽夜夜摸| 日本猛色少妇xxxxx猛交久久| a级毛色黄片| 伦理电影大哥的女人| 色吧在线观看| 熟女人妻精品中文字幕| 久久久久国产网址| 高清av免费在线| 国产亚洲一区二区精品| 免费观看av网站的网址| 青青草视频在线视频观看| av线在线观看网站| 久久99精品国语久久久| 一本久久精品| 80岁老熟妇乱子伦牲交| 99久久精品热视频| 人妻少妇偷人精品九色| 久久久久国产网址| 97在线视频观看| 亚洲精品456在线播放app| 国产熟女欧美一区二区| 日本爱情动作片www.在线观看| 久久精品国产鲁丝片午夜精品| 亚洲精品aⅴ在线观看| 亚洲精品久久午夜乱码| 日韩电影二区| 亚洲欧美成人综合另类久久久| 国产片特级美女逼逼视频| 欧美日本视频| 九九久久精品国产亚洲av麻豆| 好男人在线观看高清免费视频| 国产成人一区二区在线| 黑人高潮一二区| 久久精品国产亚洲网站| 欧美xxⅹ黑人| 一夜夜www| 亚洲在线自拍视频| av国产免费在线观看| 最近手机中文字幕大全| 久久精品国产亚洲av涩爱| 日韩大片免费观看网站| 久久人人爽人人片av| 亚洲色图av天堂| 日本猛色少妇xxxxx猛交久久| 如何舔出高潮| 日韩一本色道免费dvd| 一区二区三区四区激情视频| 国产精品麻豆人妻色哟哟久久 | 内地一区二区视频在线| 成人毛片a级毛片在线播放| 日本av手机在线免费观看| 午夜久久久久精精品| 免费高清在线观看视频在线观看| 毛片女人毛片| 免费大片黄手机在线观看| 亚洲国产欧美在线一区| 亚洲精品一区蜜桃| 日韩一本色道免费dvd| 国产成人a∨麻豆精品| 一级毛片aaaaaa免费看小| 美女大奶头视频| 毛片女人毛片| .国产精品久久| 男女边吃奶边做爰视频| 欧美高清性xxxxhd video| 国产淫片久久久久久久久| 看黄色毛片网站| 国产一区二区在线观看日韩| 人妻少妇偷人精品九色| 国产精品.久久久| 精品久久久久久久久av| 熟妇人妻不卡中文字幕| 精品人妻视频免费看| 亚洲四区av| 高清视频免费观看一区二区 | 日韩在线高清观看一区二区三区| 国产成人精品婷婷| 又爽又黄a免费视频| 日韩精品青青久久久久久| 国模一区二区三区四区视频| 精品少妇黑人巨大在线播放| av一本久久久久| 亚洲av在线观看美女高潮| 2022亚洲国产成人精品| 五月天丁香电影| 欧美激情久久久久久爽电影| av在线天堂中文字幕| 国产 一区 欧美 日韩| 亚洲欧美精品专区久久| 午夜激情欧美在线| 国内精品美女久久久久久| 免费观看性生交大片5| 大又大粗又爽又黄少妇毛片口| 精品久久久久久久久亚洲| 熟女人妻精品中文字幕| 国产一级毛片七仙女欲春2| 成人午夜高清在线视频| 国产在线男女| xxx大片免费视频| 亚洲精品国产av蜜桃| 久久久亚洲精品成人影院| 能在线免费看毛片的网站| 日韩欧美一区视频在线观看 | 国产欧美日韩精品一区二区| 国内揄拍国产精品人妻在线| 亚洲欧美一区二区三区国产| 免费观看在线日韩| 男女视频在线观看网站免费| 国产精品不卡视频一区二区| 久久精品综合一区二区三区| 精品国内亚洲2022精品成人| 亚洲欧洲国产日韩| 18禁动态无遮挡网站| 午夜日本视频在线| 水蜜桃什么品种好| 欧美区成人在线视频| 深爱激情五月婷婷| 中文字幕av在线有码专区| 99久久中文字幕三级久久日本| 蜜桃亚洲精品一区二区三区| 日韩av不卡免费在线播放| 婷婷色综合www| 国产精品一区二区三区四区免费观看| 一夜夜www| 国产在线男女| 亚洲欧洲日产国产| 国产免费又黄又爽又色| 美女国产视频在线观看| 亚洲精品乱码久久久v下载方式| 2021天堂中文幕一二区在线观| 在线免费十八禁| 三级男女做爰猛烈吃奶摸视频| 欧美日韩视频高清一区二区三区二| 一级毛片aaaaaa免费看小| 亚洲av.av天堂| 亚洲精品456在线播放app| 亚洲精品自拍成人| 日韩 亚洲 欧美在线| 精品国产一区二区三区久久久樱花 | 大陆偷拍与自拍| 最近中文字幕高清免费大全6| 国产成人午夜福利电影在线观看| 久久久久久久午夜电影| 大又大粗又爽又黄少妇毛片口| 久久久久久伊人网av| 91精品国产九色| freevideosex欧美| 亚洲精品第二区| 我的老师免费观看完整版| 精品久久久精品久久久| 亚洲av二区三区四区| 久久99热这里只频精品6学生| 久久久久久久久中文| 777米奇影视久久| 亚洲av在线观看美女高潮| 3wmmmm亚洲av在线观看| 美女高潮的动态| 午夜福利高清视频| 亚洲国产精品成人久久小说| 身体一侧抽搐| 毛片女人毛片| 精品一区二区三区人妻视频| 99久久精品国产国产毛片| 老司机影院毛片| 乱人视频在线观看| 91精品一卡2卡3卡4卡| 亚洲欧洲日产国产| 久久久精品免费免费高清| 国产精品一区二区三区四区久久| 丝袜喷水一区| 美女黄网站色视频| 国产一区有黄有色的免费视频 | 亚洲精品456在线播放app| 免费高清在线观看视频在线观看| 狂野欧美白嫩少妇大欣赏| 国产免费一级a男人的天堂| 亚洲欧美清纯卡通| 国产熟女欧美一区二区| 亚洲精品国产av成人精品| 波野结衣二区三区在线| 毛片一级片免费看久久久久| 三级经典国产精品| av卡一久久| 人妻制服诱惑在线中文字幕| 丝袜美腿在线中文| www.av在线官网国产| 久久综合国产亚洲精品| 内射极品少妇av片p| 亚洲av电影在线观看一区二区三区 | 不卡视频在线观看欧美| 日本av手机在线免费观看| 久久久久免费精品人妻一区二区| 最近视频中文字幕2019在线8| 国产午夜精品一二区理论片| 青春草亚洲视频在线观看| 小蜜桃在线观看免费完整版高清| 国产高清国产精品国产三级 | 亚洲在线自拍视频| 亚洲av成人av| 欧美潮喷喷水| 色哟哟·www| 午夜精品一区二区三区免费看| 亚洲一级一片aⅴ在线观看| 久久久久久久久久久丰满| 少妇丰满av| 中文字幕制服av| 3wmmmm亚洲av在线观看| 国产久久久一区二区三区| 久久精品夜夜夜夜夜久久蜜豆| 成人亚洲精品av一区二区| 日韩欧美精品v在线| 国产乱来视频区| 国产亚洲5aaaaa淫片| 三级毛片av免费| 国内少妇人妻偷人精品xxx网站| 成人性生交大片免费视频hd| 亚洲精品视频女| 在线免费十八禁| 国产高潮美女av| 成年人午夜在线观看视频 | 性色avwww在线观看| 成人亚洲欧美一区二区av| 欧美xxxx黑人xx丫x性爽| 国产男女超爽视频在线观看| 97热精品久久久久久| 国产精品一区二区在线观看99 | 国产成人freesex在线| 亚洲av一区综合| 久久精品国产亚洲av涩爱| 搡老妇女老女人老熟妇| 国产白丝娇喘喷水9色精品| 色播亚洲综合网| 国产白丝娇喘喷水9色精品| 天天躁日日操中文字幕| 肉色欧美久久久久久久蜜桃 | 亚洲av成人精品一区久久| 亚州av有码| 欧美97在线视频| 国产成人免费观看mmmm| 国产大屁股一区二区在线视频| 99久久精品热视频| 亚洲不卡免费看| 久久99热这里只有精品18| 99久久人妻综合| 亚洲av.av天堂| av在线老鸭窝| 亚州av有码| 免费观看精品视频网站| 国产精品爽爽va在线观看网站| 97超碰精品成人国产| 中国国产av一级| 亚洲,欧美,日韩| 一区二区三区四区激情视频| 大陆偷拍与自拍| 美女cb高潮喷水在线观看| 身体一侧抽搐| 亚洲精品第二区| 国产黄频视频在线观看| 成人鲁丝片一二三区免费| 国产真实伦视频高清在线观看| 91精品国产九色| 又大又黄又爽视频免费| 久久久a久久爽久久v久久| 亚洲av免费在线观看| 黄色欧美视频在线观看| 精品久久国产蜜桃| 最近最新中文字幕大全电影3| 亚洲精品日韩在线中文字幕| 免费观看av网站的网址| 日韩强制内射视频| 国产淫语在线视频| 国产精品人妻久久久影院| 国产精品蜜桃在线观看| 久久热精品热| 六月丁香七月| 91狼人影院| 噜噜噜噜噜久久久久久91| 成人一区二区视频在线观看| 久久久久久伊人网av| 亚洲精品中文字幕在线视频 | 尾随美女入室| 免费不卡的大黄色大毛片视频在线观看 | 少妇的逼水好多| 亚洲精品乱久久久久久| 特大巨黑吊av在线直播| 神马国产精品三级电影在线观看| 禁无遮挡网站| 国产精品一区二区三区四区免费观看| 久久久精品欧美日韩精品| 青春草视频在线免费观看| 国产精品一及| 国产91av在线免费观看| 亚洲欧美精品专区久久| 亚洲人与动物交配视频| 亚洲av日韩在线播放| 欧美日韩国产mv在线观看视频 | 国产乱来视频区| 大话2 男鬼变身卡| 好男人在线观看高清免费视频| 亚洲精品自拍成人| 成人亚洲精品av一区二区| 国产成人免费观看mmmm| 成人午夜精彩视频在线观看| 一夜夜www| 老司机影院毛片| 好男人在线观看高清免费视频| 在线观看av片永久免费下载| 免费看日本二区| 亚洲国产精品专区欧美| 欧美潮喷喷水| 69人妻影院| 国产精品1区2区在线观看.| 一个人免费在线观看电影| 午夜免费观看性视频| 亚洲av免费在线观看| 美女主播在线视频| 天天躁日日操中文字幕| 女人久久www免费人成看片| 久久99热这里只频精品6学生| 91狼人影院| 在线观看美女被高潮喷水网站| av在线亚洲专区| 18禁在线播放成人免费| 精品久久久久久久人妻蜜臀av| 国产成人精品婷婷| 国产精品麻豆人妻色哟哟久久 | 亚洲人与动物交配视频| 国产精品久久久久久久电影| 欧美成人a在线观看| 天天一区二区日本电影三级| 国产精品日韩av在线免费观看| 精品久久久噜噜| 亚洲国产av新网站| 禁无遮挡网站| 久久久久性生活片| 国产精品1区2区在线观看.| 青春草亚洲视频在线观看| 高清在线视频一区二区三区| 国产三级在线视频| 乱系列少妇在线播放| 国产成人精品久久久久久| 亚洲欧美清纯卡通| 最近中文字幕2019免费版| 国产精品久久久久久av不卡| 免费大片黄手机在线观看| av在线播放精品| 日韩,欧美,国产一区二区三区| 午夜亚洲福利在线播放| 欧美日本视频| 舔av片在线| 亚洲欧美成人精品一区二区| 激情 狠狠 欧美| 中文字幕av在线有码专区| 一级毛片电影观看| 中文字幕av在线有码专区| 亚洲精品国产成人久久av| 人人妻人人看人人澡| 男女国产视频网站| 久久久欧美国产精品| 狂野欧美激情性xxxx在线观看| 少妇的逼水好多| 青春草亚洲视频在线观看| 国产成人一区二区在线| 国产综合精华液| 国产探花极品一区二区| 一区二区三区乱码不卡18| 久久久午夜欧美精品| 国产久久久一区二区三区| 有码 亚洲区| 大香蕉久久网| 久99久视频精品免费| 免费观看a级毛片全部| 亚洲在线自拍视频| 嫩草影院新地址| 国内精品美女久久久久久| 一级av片app| 国产精品人妻久久久影院| 欧美激情国产日韩精品一区| 国内精品宾馆在线| 少妇人妻一区二区三区视频| 国产成人精品一,二区| 欧美性感艳星| 插逼视频在线观看| 韩国高清视频一区二区三区| 我的女老师完整版在线观看| 亚洲无线观看免费| 一个人观看的视频www高清免费观看| 欧美精品一区二区大全| 熟妇人妻不卡中文字幕| a级毛片免费高清观看在线播放| 一个人看的www免费观看视频| 成人av在线播放网站| 久久久久精品久久久久真实原创| 天堂av国产一区二区熟女人妻| 一个人观看的视频www高清免费观看| 国内少妇人妻偷人精品xxx网站| 久久久久久久国产电影| 国产精品三级大全| 成年版毛片免费区| 在线免费观看不下载黄p国产| 精品一区二区免费观看| 久久亚洲国产成人精品v| 最近手机中文字幕大全| 美女大奶头视频| 青春草视频在线免费观看| 丝袜美腿在线中文| 亚洲精品亚洲一区二区| 亚洲天堂国产精品一区在线| 综合色丁香网| 日本黄大片高清| 午夜精品国产一区二区电影 | 精品午夜福利在线看| 国产一区二区三区综合在线观看 | 一区二区三区乱码不卡18| 2021天堂中文幕一二区在线观| 国产精品麻豆人妻色哟哟久久 | 国产一区有黄有色的免费视频 | 亚洲精品一二三| 亚洲综合精品二区| 亚洲精品日韩av片在线观看| 久久久久久久久久久丰满| 亚洲av福利一区| av专区在线播放| 汤姆久久久久久久影院中文字幕 | 一级毛片电影观看| 国产成人午夜福利电影在线观看| 欧美性感艳星| 一个人看视频在线观看www免费| 欧美一区二区亚洲| 国产一区二区三区综合在线观看 | 成人特级av手机在线观看| 国产精品一区二区在线观看99 | 22中文网久久字幕| 又爽又黄a免费视频| 视频中文字幕在线观看| 欧美精品一区二区大全| 精品亚洲乱码少妇综合久久| 欧美日韩视频高清一区二区三区二| 国产免费一级a男人的天堂| 亚洲精品乱码久久久v下载方式| 乱人视频在线观看| 三级国产精品欧美在线观看| 欧美成人午夜免费资源| 激情 狠狠 欧美| 成年女人看的毛片在线观看| 中文字幕免费在线视频6| 国产高清国产精品国产三级 | 亚洲成人av在线免费| 干丝袜人妻中文字幕| 麻豆国产97在线/欧美| 最近中文字幕2019免费版| 91精品国产九色| 激情五月婷婷亚洲| 成年女人看的毛片在线观看| 精品久久久久久成人av| 亚洲av电影在线观看一区二区三区 | ponron亚洲| 中文在线观看免费www的网站| 搡老妇女老女人老熟妇| 久久精品人妻少妇| 又黄又爽又刺激的免费视频.| 亚洲aⅴ乱码一区二区在线播放| 亚洲精品乱码久久久久久按摩| 99热这里只有是精品50| 卡戴珊不雅视频在线播放| 国产精品福利在线免费观看| 成人欧美大片|